Whether or not a patient with ulcerative colitis should keep taking biologics is analyzed based on his or her condition, treatment plan, and the presence of complications, and usually the course of treatment takes 1-2 years or longer. The treatment of ulcerative colitis is mainly aimed at controlling acute exacerbations, maintaining remission, minimizing recurrences as well as combating complications. Maintenance therapy in internal medicine usually involves long-term medication, such as the biologic injectable infliximab, and although there is no consensus on the duration of therapy, most of them are 1-2 years and beyond, and the exact duration of therapy should be decided according to the condition and so on. The disease has a chronic course, with most patients experiencing recurrent episodes, and the prognosis is better for those with mild and prolonged remission. However, complications such as infection, toxic megacolon, or elderly patients will have a relatively poor prognosis. If the patient is diagnosed with ulcerative colitis, it is recommended to go to a regular hospital in time, after clarifying the cause of the disease, targeted treatment under the guidance of the doctor, to avoid delaying the condition.